ArticleCancers2022

A Real-World Multicentre Retrospective Study of Low-Dose Apatinib for Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer.

Tianyu Zeng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.